3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
15
Carcinoma, Transitional Cell
15
Urologic Neoplasms
4
Ureteral Neoplasms
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Neoplasms
3
Urethral Neoplasms
2
Metastatic Urothelial Cancer
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Urothelial Cancer
1
Urologic Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Urinary Bladder Diseases
1
Triple Negative Breast Neoplasms
1
Peripheral Nervous System Diseases
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms by Site
1
Neoplasm Metastasis
1
Muscle-invasive Bladder Cancer
1
Metastatic Urothelial Cancer and Other Malignant Solid Tumors
1
Male Urogenital Diseases
1
Head and Neck Neoplasms
1
Female Urogenital Diseases
1
Esophageal Neoplasms
1
Carcinoma in Situ
1
Advanced Solid Tumor
1
Interventions
Mitomycin
3
vofatamab
2
pembrolizumab
2
B701 protein, Human herpesvirus 6
2
valrubicin
1
trifluridine tipiracil drug combination
1
palbociclib
1
enfortumab vedotin
1
atezolizumab
1
Water
1
Sunitinib
1
Standard of Care
1
Radiation Dose Hypofractionation
1
Gemcitabine
1
Gels
1
Fluorouracil
1
Docetaxel
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Urologic Diseases
×
enfortumab vedotin
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled